This project has been flagged by a community member as inappropriate due to reason below.*
Expert Interview
Slingshot members are talking to an expert! The topic is:
A Second look at the differences between Cimerli anti-VEGF vs Lucentis as therapy for Wet-AMD
Ticker(s): CHRS, RHHBYWho's the expert?
Institution: UCSF
- Currently employed at UCSF Medical Center, since September 2021, holding the title of Assistant
Professor of Ophthalmology and Vitreoretinal Surgery. - Currently manages ~200 Wet-AMD pts
- Co-Founder of the Loving Eyes Foundation, a non profit organization that provides children
with craniofacial malformations custom glasses.
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
